• EV-303: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (Cisplatin-ineligible)
  • https://www.nejm.org/doi/full/10.1056/NEJMoa2511674
• EV-304: Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
  • https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.LBA630
• However, SOC for cisplatin eligible is cis/gem/durva
  • NIAGARA: Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
  • https://www.nejm.org/doi/full/10.1056/NEJMoa2408154